Aurobindo Pharma Expands US Presence with FDA Approval and Major Biologics Manufacturing Push

$AUROPHARMA has strengthened its position in the global pharmaceutical market after receiving final US FDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths, a treatment used for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. The product is equivalent to Xeljanz and will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary, with an immediate commercial launch planned. The US market for Tofacitinib Tablets is estimated at approximately $494 million based on the latest 12-month data ending April 2026. With this approval, Aurobindo's cumulative US FDA approvals have reached 586 ANDAs, comprising 561 final approvals and 25 tentative approvals, highlighting its strong presence in the generic pharmaceutical space. In another strategic development, the company recently inaugurated TheraNym, a dedicated biologics contract manufacturing organization near Hyderabad, marking its entry into the fast-growing biologics manufacturing segment. Positioned as one of India's largest dedicated biologics contract manufacturing facilities, TheraNym has already secured MSD (Merck & Co. in the US and Canada) as its anchor customer. These developments reflect Aurobindo Pharma's continued focus on expanding its product portfolio, strengthening manufacturing capabilities and enhancing its long-term growth prospects across both generics and biologics markets. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.